The second quarter of 2025 saw a surge in mergers and acquisitions (M&A) within the pharmaceutical and biotechnology industry, picking up momentum after a relatively subdued 2024. From March through June 2025, dealmaking accelerated across all tiers of the market – from small startup takeouts to multibillion-dollar buyouts.

It is a truth almost universally acknowledged—except, perhaps, in FDA review meetings—that no credible scientist gets funded anymore without first referencing Star Trek. Beam me up? More like bill me out. Flip phones? Inspired by Kirk. Tablets? Also Kirk. Diagnostic AI? McCoy had one strapped to his wrist

The decades-long puzzle of protein folding In the pantheon of scientific challenges, few have loomed as large or as stubborn as the protein folding problem. First posed in the 20th century, it asked how a mere string of amino acids — a one-dimensional sequence — can spontaneously contort into a

When a small Berlin startup launched an obesity therapy app a few years ago, investors hailed it as a potential game-changer. With slick design and AI coaching, it promised to slim waistlines and fatten venture returns. The app’s code worked beautifully – but the business case didn’t. Germany’

Real-World Data (RWD) is the equivalent of field notes in anthropology: messy, unstructured, but full of valuable insights about how things work in the real world. Unlike randomized controlled trials (RCTs), which operate in the sterile confines of idealized conditions, RWD is collected from routine clinical care, patient registries,

Startups are curious beasts. They move fast, break things, raise millions, and yet remain spectacularly unable to define who is actually in charge of scheduling the Zoom calls. Titles abound—Founder, CEO, President, Principal Evangelist of Crypto-Enabled Omnichannel Innovation—and yet actual leadership is often thinner than a Series

Introduction: Platforms, Promise, and the VC Paradox Biotechnology has always been a high-stakes endeavor, with the odds stacked against any single drug making it to market. In recent years, a specific “platform company” model has risen to prominence. These are startups built around a versatile technology or modality – from

If you’ve been through business school, corporate training, or an executive retreat, chances are you’ve encountered the holy relics of management thinking: SWOT analyses, Porter’s Five Forces, RACI matrices, and SMART criteria. They’re taught with reverence, like ancient scriptures handed down from the mountaintop, even though

Strategy was once a noun. Then someone turned it into a 2x2 matrix and started charging €400/hour for it. In the beginning was the memo. Then came the workshop. And lo, the workshop begat the brainstorm, and the brainstorm begat The Framework™. And thus the modern consultant emerged, blinking

Foundations of a Gene Therapy Pioneer (1992–2010) bluebird bio began not as the vibrant name suggests, but as a modest startup called Genetix Pharmaceuticals in April 1992. Founded by two MIT researchers, Philippe Leboulch and Irving London, the company was grounded in a radical idea for its time: using